DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/xmglmf/sustained_release) has announced the addition of the “Sustained Release Ocular Drug Delivery Systems, 2015 – 2025 (2nd edition)” report to their offering. …
Anyone who has ever broken an arm or a leg knows full well how bulky and unwieldy conventional casts are. A group of engineers wanted to improve the experience and make casts more than just rigid structures to hold bones in place. The BoomCast is 3D printed based on a scan of a person’s leg […]
Anyone who has ever broken an arm or a leg knows full well how bulky and unwieldy conventional casts are. A group of engineers wanted to improve the experience and make casts more than just rigid structures to hold bones in place. The BoomCast is 3D printed based on a scan of a person’s leg […]
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the second quarter ended June 30, 2015 along with a general business update. Aerie Highlights Efficacy results from Aerie’s RhopressaTM Rocket 2 trial, using the primary clinical endp
BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation (NASDAQ: BRKR) today reported financial results for its second quarter ended June 30, 2015. Bruker’s revenues for the second quarter of 2015 were $396.0 million, a decline of 13.4 percent compared to the second quarter of 2014. Excluding a 2.6 percent negative effect from divestitures, and an 11.5 percent negative effect from changes in foreign exchange rates, Bruker reported year-over-year organic revenue growth of 0.7 percent in the second
IRVINE, Calif. & BALTIMORE–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, and GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degenera